EP3700903A1 - Imidazopyridinamides substituées et leur utilisation - Google Patents

Imidazopyridinamides substituées et leur utilisation

Info

Publication number
EP3700903A1
EP3700903A1 EP18785687.7A EP18785687A EP3700903A1 EP 3700903 A1 EP3700903 A1 EP 3700903A1 EP 18785687 A EP18785687 A EP 18785687A EP 3700903 A1 EP3700903 A1 EP 3700903A1
Authority
EP
European Patent Office
Prior art keywords
heart failure
acid
imidazo
ethyl
μιηοΐ
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP18785687.7A
Other languages
German (de)
English (en)
Inventor
Daniel Meibom
Jutta Meyer
Karl COLLINS
Nuria Ortega Hernandez
Jan Stampfuss
Frank Wunder
Till FREUDENBERGER
Thomas MONDRITZKI
Nina Alexandra SCHEERER
Kirsten LEINEWEBER
Jens Schamberger
Alexander Straub
Matthias Gericke Kersten
Walter Kroh
Mario Lobell
Klaus Münter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Bayer Pharma AG
Original Assignee
Bayer AG
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60162133&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP3700903(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer AG, Bayer Pharma AG filed Critical Bayer AG
Publication of EP3700903A1 publication Critical patent/EP3700903A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Definitions

  • the present application relates to novel substituted Imidazopyridinamide, processes for their preparation, their use alone or in combinations for the treatment and / or prophylaxis of diseases and their use for the preparation of medicaments for the treatment and / or prophylaxis of diseases, in particular for the treatment and / or prophylaxis of cardiovascular, neurological and central nervous as well as metabolic diseases.
  • the a-2B adrenoreceptor belongs to the group of adrenoreceptors that are activated by the natural messengers adrenaline and norepinephrine and are thus responsible for the epinephrine and norepinephrine mediated effects.
  • the a-2B adrenergic receptor is a G-protein coupled receptor (GPCR) associated with the Gori inhibitory signaling pathway.
  • the receptor is expressed centrally in the brain as well as peripherally on vascular smooth muscle cells and centrally mediates sodium retention as well as peripheral vasoconstriction (Am J Physiol Regulatory Integrative Comp Physiol. 2002; 283: R287-295). Also highly expressed is the receptor in the kidney (Clin Sei (Lond) 2005; 109 (5): 431-7), where it may play a role in kidney perfusion and diuresis (International Journal of Cardiology 2004; 97: 367- 372nd
  • ADRA2B G-protein receptor kinase dependent phosphorylation
  • GRK G-protein receptor kinase
  • This desensitization and internalization of the receptor with continued stimulation of the receptor with the agonist, leads to decreased activation of the downstream signaling cascade (G protein activation) and thus reduced cell responsiveness to the agonist.
  • G protein activation G protein activation
  • ADRA2B genetic DD variant there is a deletion of 3 glutamic acids in the 3rd intracellular loop of the receptor, which reduces agonist-induced receptor phosphorylation and desensitization. This results in prolonged activation of the receptor and the signaling cascade after agonist stimulation (Cell Commun Signal, 2011; 9 (1): 5).
  • ADRA2B DD variant A number of studies have shown a significant association of the ADRA2B DD variant with the occurrence of certain diseases. In the normal population, depending on ethnicity, 20-30% of people carry the DD variant of the receptor. In patients with heart disease, the proportion of carriers of the DD variant increases to almost 50%. Thus, the DD variant is significantly associated with the onset of myocardial infarction and sudden cardiac death in humans (J Am Coli Cardiol 2003, 41 (2): 190-4, J Am Coli Cardiol 2001, 37 (6): 1516-22 ).
  • ADRA2B is significantly associated with the occurrence of ischemic strokes. This also seems to be due to a dysfunction of the small vessels (Clin Neurol Neurosurg. 2013; 115 (1): 26-31).
  • association studies indicate a pathomechanistic importance of the ADRA2B receptor - regardless of genotype - in ischemic diseases, especially ischemic heart disease.
  • PTSD posttraumatic stress disorder
  • Norepinephrine is involved as a neurotransmitter in the processing of emotional memory processes.
  • the DD variant of the ADRA2B receptor is thought to result in enhanced norepinephrine in response to emotional events, leading to increased amygdala activation and increased emotional memory. Increased amygdala activation correlates with severity of symptoms in patients with PTSD.
  • New therapeutic strategies to reduce infarct size and maintain cardiac function are needed to improve patient survival and prevent the development of heart failure following myocardial infarction.
  • the object of the present invention was the identification and provision of novel, low-molecular compounds which act as potent antagonists of the ADRA2B receptor and are thus suitable for the treatment and / or prevention of cardiovascular, neurological and central nervous as well as metabolic diseases.
  • ADRA2B antagonists for use in myocardial infarction patients, in particular for the reduction of reperfusion damage.
  • ADRA2B inhibitors are described, for example, in WO 03/008387 and in WO2010 / 033393.
  • WO2009 / 47506 and WO2009 / 47522 refer to imidazopyridinecarboxamides
  • Tyrosine kinase inhibitors disclosed.
  • imidazopyridine derivatives are known which act as phosphatidylinositol-3-kinase (P13K) inhibitors and can thus be used as antitumor agents.
  • P13K phosphatidylinositol-3-kinase
  • WO 2008/027812 imidazopyridines and imidazopyrimidine derivatives are published which act as cannabinoid receptor ligands, eg CB2 ligands.
  • WO 2008/134553 describes bicyclic compounds which can be used inter alia for the treatment of pain.
  • Imidazopyridine derivatives as modulators of TNF activity are described in WO 2014/009295.
  • the compounds of the present invention have surprising and advantageous properties which achieve the object of the present invention.
  • the compounds of the present invention are ADRA2B antagonists.
  • the compounds of the invention are due to their good solubility for parenteral administration forms (European Pharmacopoeia 6th edition, basic work (Ph.Eur., 6.0), p 1024) and thus open up new treatment options.
  • the compounds mentioned are particularly suitable for acute therapy such as acute administration during percutaneous coronary intervention, as well as other acute situations that can lead to reduced perfusion and organ damage (heart, kidney, brain).
  • the present invention relates to compounds of the formula (I)
  • R 1 , R 2 , and R 3a , R 3b independently of one another are selected from the group consisting of hydrogen, amino, (C 1 -C 4) -alkyl, (C 1 -C 4) -alkoxy, and mono- (C 1 -C 4) - alkylamino, di- (Ci-C4) -alkylamino, phenoxy and piperidin-lyl, where phenoxy and piperidin-lyl, with (Ci-C4) alkyl and / or fluorine may be substituted and wherein the alkyl groups in (Ci-C4 ) Alkyl, (C 1 -C 4) -alkoxy mono- (C 1 -C 4) -alkylamino and di- (C 1 -C 4) -alkylamino each may be substituted by up to five times with fluorine,
  • R 4 is (C 1 -C 4 ) -alkyl which may be substituted by fluorine up to five times or represents a group of the formula CH 2 CN, CH 2 CONH 2 , D for a heteroaromatic of the formula
  • R 5 and R 6 independently of one another represent hydrogen, (Ci-C i) -alkyl or (Ci-C i) -alkoxy, where (Ci-C i) -alkyl and (Ci-C i ) Alkoxy may each be substituted by up to five times with fluorine, L is CH 2 , n is the number 0, 1, 2 or 3 and
  • X is a physiologically acceptable anion, as well as, solvates, salts and solvates of the salts of the compounds of formula (I).
  • the present invention also includes convenient forms of the compounds of the present invention, such as metabolites, hydrates, solvates, prodrugs, salts, especially pharmaceutically acceptable salts, and / or co-precipitates.
  • the compounds of the formula (I) according to the invention are already in salt form but may still form further addition salts.
  • Compounds according to the invention are the compounds of the formula (I) and their salts, solvates and solvates of the salts comprising the compounds of the formulas below and their salts, solvates and solvates of the salts and of the formula (I) encompassed by formula (I), hereinafter referred to as exemplary compounds and their salts, solvates and solvates of the salts, as far as the compounds of formula (I), the compounds mentioned below are not already salts, solvates and solvates of the salts.
  • Salts used in the context of the present invention are physiologically acceptable salts of the compounds according to the invention. Also included are salts which are themselves unsuitable for pharmaceutical applications but can be used, for example, for the isolation or purification of the compounds of the invention.
  • pharmaceutically acceptable salt refers to an inorganic or organic acid addition salt of a compound according to the present invention See, for example, SM Berge, et al., "Pharmaceutical Salts", J. Pharm. 1977, 66, 1 -19. - -
  • a suitable pharmaceutically acceptable salt of the compounds of the present invention may be, for example, an acid addition salt of a compound of the present invention, such as an acid addition salt with an inorganic acid or "mineral acid", for example, hydrochloric, hydrofluoric, hydrobromic, hydroiodic, Sulfuric acid, sulfamic acid, disulfuric acid, phosphoric acid or nitric acid, or with an organic acid such as formic acid, acetic acid, acetoacetic acid, pyruvic acid, trifluoroacetic acid, propionic acid, butyric acid, hexanoic acid, heptanoic acid, undecanoic acid, lauric acid, benzoic acid, salicylic acid, 2- (4-hydroxybenzoyl ) benzoic acid, camphoric acid, cinnamic acid, cyclopentanopropionic acid, digluconic acid, 3-hydroxy-2-naphthoic acid, nicotinic acid, pamoi
  • acid addition salts of the claimed compounds can be prepared by reacting the compounds with the corresponding inorganic or organic acid by a number of known methods.
  • the present invention includes all possible salts of the compounds of the present invention as individual salts or as a mixture of these salts in any proportion.
  • Physiologically acceptable anions in the context of the present invention are the anions of mineral acids, carboxylic acids and sulfonic acids, for example hydrochloric acid, hydrofluoric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, benzenesulfonic acid, naphthalenedisulfonic acid, formic acid, acetic acid, trifluoroacetic acid, Propionic acid, lactic acid, tartaric acid, malic acid, citric acid, fumaric acid, maleic acid and benzoic acid.
  • mineral acids for example hydrochloric acid, hydrofluoric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, benzenesulfonic acid, naphthal
  • anions of the following acids hydrochloric acid, hydrobromic acid, formic acid.
  • Particularly preferred are anions of hydrochloric acid, hydrobromic acid and formic acid.
  • Solvates in the context of the invention are those forms of the compounds according to the invention which form a complex in the solid or liquid state by coordination with solvent molecules. Hydrates are a special form of solvates that coordinate with water. As solvates, hydrates are preferred in the context of the present invention.
  • the compounds according to the invention may exist in different stereoisomeric forms, ie in the form of configurational isomers or optionally also as conformational isomers (enantiomers and / or diastereomers, including those in the case of atropisomers).
  • the present invention therefore encompasses the enantiomers and diastereomers and their respective mixtures.
  • the stereoisomerically uniform components can be isolated in a known manner;
  • chromatographic methods are used for this, in particular HPLC chromatography on achiral or chiral phase.
  • separation may be effected via diastereomeric salts with the aid of chiral amine bases.
  • the present invention encompasses all tautomeric forms.
  • the positively charged aza-heteroaromatics in addition to the formula A shown, can also be present in the respective mesomeric boundary structures, which are to be encompassed by the representation A, in particular the following limit structure:
  • the compounds of the general formula (I) can be present as isotopic variants.
  • the invention therefore comprises one or more isotopic variants of the compounds of the general formula (I), in particular deuterium-containing compounds of the general formula (I).
  • isotopic variant of a compound or reagent is defined as a compound having an unnatural portion of one or more of the isotopes of which such a compound is constructed.
  • isotopic variant of the compound of general formula (I) is defined as a compound of general formula (I) having an unnatural portion of one or more of the isotopes constituting such a compound.
  • isotope By the term “unnatural fraction” is meant a proportion of such an isotope that is higher than its natural abundance.
  • the natural frequencies of isotopes to be used in this context can be found in "Isotopic Compositions of the Elements 1997", Pure Appl. Chem., 70 (1), 217-235, 1998. - -
  • isotopes are stable and radioactive isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, bromine and iodine, such as 2 H (deuterium), 3 H (tritium), U C, 13 C, 14 C, 15 N, 17 0, 18 0, 32 P, 33 P, 33 S, 34 S, 35 S, 36 S, 18 F, 36 C1, 82 Br, 123 I, 124 I, 125 I, 129 I or 131 I.
  • isotopes are stable and radioactive isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, bromine and iodine, such as 2 H (deuterium), 3 H (tritium), U C, 13 C, 14 C, 15 N, 17 0, 18 0, 32 P, 33 P, 33 S, 34 S, 35 S, 36 S, 18 F, 36 C1, 82 Br, 123 I, 124 I, 125 I, 129 I or 131 I.
  • the isotopic variant (s) of the compounds of the general formula (I) preferably contain deuterium ("deuterium-containing compounds of the general formula (I)").
  • Isotopic variants of the compounds of the general formula (I) incorporating one or more radioactive isotopes such as 3 H or 14 C are useful, for example, in drug and / or substrate tissue distribution studies. These isotopes are particularly preferred for their ease of installation and detectability.
  • positron-emitting isotopes such as 18 F or U C can be incorporated.
  • These isotopic variants of the compounds of general formula (I) are suitable for use in in vivo imaging applications.
  • Deuterium-containing and 13 C-containing compounds of the general formula (I) can be used in pre-clinical or clinical studies in mass spectrometry analyzes.
  • Isotopic variants of the compounds of general formula (I) can generally be prepared by methods known to those skilled in the art, such as those described in the Schemes and / or Examples described herein, by replacing a reagent with an isotopic variant of the reagent, preferably a deuterium-containing reagent , Depending on the desired deuteration sites, in some cases deuterium may be incorporated from D 2 O either directly into the compounds or into reagents that may be used for the synthesis of such compounds.
  • a useful reagent for incorporating deuterium into molecules is also deuterium gas.
  • a rapid route to the incorporation of deuterium is the catalytic deuteration of olefinic bonds and acetylenic bonds.
  • metal catalysts ie Pd, Pt and Rh
  • deuterium gas may also be used.
  • Various deuterated reagents and building blocks are commercially available from companies such as C / D / N Isotopes, Quebec, Canada; Cambridge Isotope Laboratories Inc., Andover, MA, USA; and CombiPhos Catalysts, Inc., Princeton, NJ, USA.
  • deuterium-containing compound of the general formula (I) is defined as a compound of the general formula (I) in which one or more hydrogen atoms are replaced by one or more deuterium atoms and in which the frequency of deuterium in each deuterated position of the compound of the general formula (I) is higher than the natural frequency of deuterium, which is about 0.015%.
  • the abundance of deuterium in each deuterated position of the compound of the general formula (I) is higher than 10%, 20%, 30%, 40%, 50%, 60%, 70%. or 80%, preferably higher than 90%, 95%, 96% or 97%, still more preferably higher than 98% or 99% in this position or these positions. It It is understood that the frequency of deuterium in each deuterated position is independent of the frequency of deuterium in other deuterated positions.
  • deuterium replacement reduces or eliminates the formation of an undesirable or toxic metabolite and enhances the formation of a desired metabolite (eg, nevirapine: AM Sharma et al., Chem. Res. Toxicol., 2013, 26, 410; Efavirenz: AE Mutlib et al., Toxicol, Appl Pharmacol., 2000, 169, 102).
  • the main effect of deuteration is to reduce the rate of systemic clearance. This increases the biological half-life of the compound.
  • Deuterated drugs that exhibit this effect may have reduced dosage rates (e.g., fewer doses or lower doses to achieve the desired effect) and / or lower metabolite levels.
  • a compound of general formula (I) may have several potential sites of metabolism.
  • deuterium-containing compounds of the general formula (I) having a specific pattern of one or more deuterium-hydrogen exchanges can be selected.
  • the deuterium atom (s) is (are) - - deuterium restroomr compound (s) of the general formula (I) bonded to a carbon atom and / or are / are in the positions of the compound of general formula (I), which are sites of attack for metabolizing enzymes such as cytochrome P450.
  • the present invention also includes prodrugs of the compounds of the invention.
  • prodrugs refers to compounds which themselves may be biologically active or inactive, but are reacted during their residence time in the body to compounds according to the invention (for example metabolically or hydrolytically).
  • Alkyl or (C 1 -C 10) -alkyl in the context of the invention is a linear or branched alkyl radical having 1 to 4 carbon atoms. Examples which may be mentioned are: methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 1-methylpropyl, tert-butyl. Preferred are methyl, ethyl and isopropyl. Particularly preferred is methyl.
  • Alkoxy or (C 1 -C 4) -alkoxy in the context of the invention is a linear or branched alkoxy radical having 1 to 4 carbon atoms. Examples which may be mentioned by way of example include: methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy and tert. Butoxy. Preferred are methoxy and ethoxy. Particularly preferred is methoxy.
  • mono-C 1 -C 4 -alkylamino means an amino group having a straight-chain or branched alkyl substituent having 1 to 4 carbon atoms.
  • the following may be mentioned: methylamino, ethylamino, n-propylamino, isopropylamino, n-butylamino, .yeo-butylamino and tert-butylamino.
  • Particularly preferred is methylamino.
  • di (C 1 -C 4 -alkylamino means an amino group having two identical or different straight-chain or branched alkyl substituents each having 1 to 4 carbon atoms.
  • Particularly preferred is dimethylamino.
  • radicals are substituted in the compounds according to the invention, the radicals can, unless otherwise specified, be monosubstituted or polysubstituted. In the context of the present invention, the meaning is independent of each other for all radicals which occur repeatedly. Substitution with one or two identical or different substituents is preferred. Very particular preference is given to the substitution with a substituent. - -
  • treatment includes inhibiting, delaying, arresting, alleviating, attenuating, restraining, reducing, suppressing, restraining or curing a disease, a disease, a disease, an injury or a medical condition , the unfolding, the course or progression of such conditions and / or the symptoms of such conditions.
  • therapy is understood to be synonymous with the term “treatment”.
  • prevention means the avoidance or reduction of the risk, a disease, a disease, a disease, an injury or a health disorder, a development or a Progression of such conditions and / or to get, experience, suffer or have the symptoms of such conditions.
  • the treatment or the prevention of a disease, a disease, a disease, an injury or a health disorder can be partial or complete.
  • R 1 , R 2 , and R 3a , R 3b independently of one another represent a group selected from hydrogen, ethylamino, dimethylamino, methylamino, amino, methyl, ethyl, trifluoromethyl, t-butyl, isopropyl, phenoxy or piperidin-1-yl,
  • R 4 is methyl
  • R 5 and R 6 are independently hydrogen, methyl, ethyl, isopropyl or methoxy
  • n is the number 1 or 2
  • X is, bromide, chloride or formate and A is a positively charged aza Heteroaromatics of the formula
  • linking site means and
  • L is CH 2 and their solvates, salts and solvates of the salts.
  • R 2 is hydrogen or methyl
  • R 3a , R 3b are hydrogen
  • R 4 is methyl
  • R 5 and R 6 independently of one another are methyl, methoxy or hydrogen, n is the number 1 or 2,
  • X is, bromide, chloride or formate
  • A is a positively charged aza heteroaromatic of the formula
  • ** is the point of attachment and L is CH 2 , and their solvates, salts and solvates of the salts.
  • Another object of the invention is a process for the preparation of the compounds of formula (I) according to the invention characterized in that a compound of formula (II) or its corresponding carboxylic acid
  • D has the abovementioned meaning
  • a condensing agent such as, for example, 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride in the presence of a base such as 4-dimethylaminopyridine with a compound of the formula (III)
  • Inert solvents for process step (II) + (III) -> (I) are, for example, halogenated hydrocarbons such as dichloromethane, trichlorethylene, chloroform or chlorobenzene, ethers such as diethyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether or diethylene glycol dimethyl ether, hydrocarbons such as benzene, toluene, xylene, Hexane, cyclohexane or petroleum fractions or other solvents such as acetonitrile, N, N-dimethylformamide, N, N-dimethylacetamide, dimethyl sulfoxide, N, N'-dimethylpropyleneurea (DMPU), N-methylpyrrolidone (NMP) or pyridine. It is likewise possible to use mixtures of the solvents mentioned. Preference is given to using dichloromethane, tetrahydrofuran or pyridine. Particular
  • Suitable condensing agents for amide formation in process step (II) + (III) -> (I) are, for example, carbodiimides such as NN'-diethyl, NN'-dipropyl, NN'-diisopropyl, NN'-dicyclo- Hexylcarbodiimide (DCC) or N- (3-dimethylaminopropyl) -N'-ethylcarbodiimide hydrochloride (EDC), phosgene derivatives such as NN'-carbonyldiimidazole (CDI), 1,2-oxazolium compounds such as 2-ethyl-5- phenyl-1, 2-oxazolium-3-sulphate or 2-ferric-butyl-5-methylisoxazolium perchlorate, acylamino compounds such as 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline, or isobutylchloroformate, propane
  • EDC EDC
  • HATU HATU
  • DCC DCC
  • T3P T3P
  • Suitable bases for amide formation in process step (II) + (III) -> ⁇ (I) are, for example, alkali metal carbonates, for example sodium or potassium carbonate or bicarbonate, or organic bases such as trialkylamines, eg triethylamine (TEA), N-methylmorpholine , N-methylpiperidine or NN-diisopropylethylamine (DIPEA) or 4- (dimethylamino) pyridine (DMAP).
  • TEA triethylamine
  • DIPEA NN-diisopropylethylamine
  • DMAP 4- (dimethylamino) pyridine
  • DMAP TEA
  • DIPEA 4- (dimethylamino) pyridine
  • the condensations (II) + (III) -> (I) is generally carried out in a temperature range from -20 ° C to + 100 ° C, preferably at 0 ° C to + 60 ° C.
  • the reaction can be carried out at normal, elevated or at reduced pressure (for example from 0.5 to 5 bar). Generally one works at room temperature and normal pressure.
  • the carboxylate of the formula (II) can also first be converted into the corresponding carboxylic acid chloride and this can then be reacted directly or in a separate reaction with a compound of the formula (III) to give the compounds according to the invention.
  • the formation of carboxylic acid chlorides from carboxylic acids is carried out by the methods known to those skilled in, for example by treatment of (II) or the corresponding free carboxylic acid with thionyl chloride, sulfuryl chloride or oxalyl chloride in the presence of a suitable base, for example in the presence of pyridine, and optionally with the addition of dimethylformamide , optionally in a suitable inert solvent.
  • bromides are obtained.
  • the remaining physiologically acceptable counteranions can be obtained from the formates, chlorides or bromides by means of ion exchangers.
  • the compounds used are commercially available, known from the literature or can be prepared analogously to processes known from the literature.
  • L, n, D, R 1 , R 2 , R 3a and R 3b are as defined above.
  • the compounds according to the invention have valuable pharmacological properties and can be used for the treatment and / or prophylaxis of diseases in humans and animals.
  • the compounds according to the invention are potent, chemically stable antagonists of the ADRA2B receptor and are therefore suitable for the treatment and / or prevention of diseases and pathological processes, in particular cardiovascular, nephrological, neurological and central nervous disorders.
  • diseases of the cardiovascular system or cardiovascular diseases are understood as meaning, for example, the following diseases: acute and chronic heart failure, arterial hypertension, coronary heart disease, stable and unstable angina pectoris, myocardial ischemia, myocardial infarction, coronary microvascular dysfunction, microvascular obstruction , no-reflow phenomenon, shock, atherosclerosis, cardiac hypertrophy, cardiac fibrosis, atrial and ventricular arrhythmias, transient and ischemic attacks, stroke, ischemic and hemorrhagic stroke, pre-eclampsia, inflammatory cardiovascular diseases, peripheral and cardiovascular diseases, peripheral circulatory disorders, peripheral arterial disease, primary and secondary Raynaud's syndrome, microcirculatory disorders, arterial pulmonary hypertension, spasms of the coronary arteries and peripheral arteries, thrombosis, thromboemb edema, such as pulmonary edema, cerebral edema, renal edema or heart failure-related edema; and restenosis such as
  • cardiac insufficiency also encompasses more specific or related forms of disease such as acute decompensated heart failure, right heart failure, left heart failure, global insufficiency, ischemic cardiomyopathy, dilated cardiomyopathy, congenital heart defects, valvular heart failure, cardiac valvulopathy, mitral valve stenosis, mitral valve insufficiency, aortic valve stenosis, aortic valve insufficiency, tricuspid stenosis, Tricuspid insufficiency, pulmonary valve stenosis, pulmonary valvular insufficiency, combined heart valve defects, myocarditis, chronic myocarditis, acute myocarditis, viral myocarditis, diabetic cardiac insufficiency, alcoholic cardiomyopathy, cardiac storage disorders, heart failure with preserved systolic pump function (HFpEF), - - Diastolic heart failure and congestive heart failure with reduced s
  • HFpEF preserved s
  • the term atrial and ventricular arrhythmias also encompasses more specific or related forms of disease such as: atrial fibrillation, paroxysmal atrial fibrillation intermittent atrial fibrillation, permanent atrial fibrillation, atrial flutter, sinus arrhythmia, sinus tachycardia, passive heterotopia, active heterotopia, surrogate bouts, extrasystoles, conduction disorders, sick sinus Syndrome, hypersensitive carotid sinus, tachycardia, AV node reentrant tachycardia, atriventricular reentrant tachycardia, WPW syndrome (Wolff-Parkinson-White), Mahaim tachycardia, hidden accessory pathway, permanent junctional reentrant tachycardia, focal atrial tachycardia, junctional ectopic tachycardia, atrial Reentry tachycardia, ventricular tachycardia, ventricular flutter, ventricular
  • coronary heart disease also encompasses more specific or related forms of disease such as: ischemic heart disease, stable angina pectoris, acute coronary syndrome, unstable angina pectoris, NSTEMI (non-ST segment elevation infarct), STEMI (ST segment elevation infarct), ischemic heart disease. muscle damage, arrhythmia, and myocardial infarction.
  • ischemic heart disease stable angina pectoris, acute coronary syndrome, unstable angina pectoris, NSTEMI (non-ST segment elevation infarct), STEMI (ST segment elevation infarct), ischemic heart disease. muscle damage, arrhythmia, and myocardial infarction.
  • diseases of the central nervous and neurological system or of central nervous and neurological disorders are understood as meaning, for example, the following disorders: transient and ischemic attacks, stroke, ischemic and hemorrhagic stroke, depression, anxiety disorders, posttraumatic stress disorder, polyneuropathy, diabetic polyneuropathy, stress - Conditional hypertension.
  • the compounds according to the invention are also suitable for the prophylaxis and / or treatment of polycystic kidney disease (PCKD) and the syndrome of inadequate ADH secretion (SIADH).
  • PCKD polycystic kidney disease
  • SIADH syndrome of inadequate ADH secretion
  • the compounds according to the invention are suitable for the treatment and / or prophylaxis of kidney diseases, in particular of acute and chronic renal insufficiency, as well as of acute and chronic renal failure.
  • the term acute renal insufficiency includes acute manifestations of kidney disease, renal failure and / or renal insufficiency with and without dialysis, as well as underlying or related renal diseases such as renal hypoperfusion, intradialytic hypotension, volume depletion (eg dehydration, blood loss), shock, acute glomerulonephritis, hemolytic uremic syndrome (HUS), vascular catastrophe (arterial or venous thrombosis or embolism), cholesterol embolism, acute Bence Jones kidney in plasmocytoma, acute supravesical or subvesical drainage obstruction, immunological kidney disease such as - -
  • Kidney transplant rejection immune complex-induced kidney disease, tubular dilatation, hyperphosphatemia and / or acute kidney disease which may be characterized by the need for dialysis, partial kidney resection, forced diuresis dehydration, uncontrolled hypertensive hypertension, urinary tract obstruction and infection and amyloidosis as well as systemic diseases with glomerular involvement, such as rheumatologic-immunological systemic diseases, such as lupus erythematosus, renal artery thrombosis, renal vein thrombosis, analgesic and nephropathic renal tubular acidosis, as well as X-ray contrast agent and drug-induced acute interstitial kidney disease.
  • rheumatologic-immunological systemic diseases such as lupus erythematosus, renal artery thrombosis, renal vein thrombosis, analgesic and nephropathic renal tubular acidosis, as well as X-ray contrast agent and drug-induced
  • chronic renal insufficiency includes chronic manifestations of kidney disease, renal failure and / or renal insufficiency with and without dialysis, as well as underlying or related renal diseases such as renal hypoperfusion, intradialytic hypotension, obstructive uropathy, glomerulopathies, glomerular and tubular proteinuria, renal edema, hematuria, primary, secondary and chronic glomerulonephritis, membranous and membranoproliferative glomerulonephritis, Alport syndrome, glomerulosclerosis, tubulointerstitial diseases, nephropathic disorders such as primary and congenital kidney disease, nephritis, immunological renal diseases such as renal transplant rejection, immune complex-induced renal disease, diabetic and nondiabetic nephropathy , Pyelonephritis, renal cysts, nephrosclerosis, hypertensive nephrosclerosis and nephrotic syndrome, which
  • the present invention also encompasses the use of the compounds of the invention for the treatment and / or prophylaxis of sequelae of renal insufficiency, such as pulmonary edema, heart failure, uremia, anemia, electrolyte imbalances (eg, hyperkalemia, hyponatremia) and disorders in bone and carbohydrate metabolism.
  • sequelae of renal insufficiency such as pulmonary edema, heart failure, uremia, anemia, electrolyte imbalances (eg, hyperkalemia, hyponatremia) and disorders in bone and carbohydrate metabolism.
  • the compounds according to the invention are also suitable for the treatment and / or prophylaxis of pulmonary arterial hypertension (PAH) and other forms of pulmonary hypertension (PH), the - 5 - chronic obstructive pulmonary disease (COPD), acute respiratory tract syndrome (ARDS), acute lung injury (ALI), alpha-1-antitrypsin deficiency (AATD), pulmonary fibrosis, pulmonary emphysema (eg, cigarette smoke-induced emphysema) , cystic fibrosis (CF), acute coronary syndrome (ACS), heart muscle inflammation (myocarditis) and other autoimmune heart disease (pericarditis, endocarditis, valvolitis, aortitis, cardiomyopathy), cardiogenic shock, aneurysms, sepsis (SIRS), multiple organ failure (MODS, MOF), inflammatory kidney diseases, chronic enteritis (IBD, Crohn's Disease, UC), pancreatitis, peritonitis, pulmonary
  • the compounds according to the invention can furthermore be used for the treatment and / or prophylaxis of asthmatic disorders of varying degrees of severity with intermittent or persistent course (refractive asthma, bronchial asthma, allergic asthma, intrinsic asthma, extrinsic asthma, medication or dust-induced asthma)
  • bronchitis chronic bronchitis, infectious bronchitis, eosinophilic bronchitis
  • bronchiolitis obliterans bronchiectasis
  • pneumonia idiopathic interstitial pneumonia, farmer's and related diseases
  • cough and colds chronic inflammatory cough, iatrogenic cough
  • nasal mucosal inflammation including drug rhinitis, vasomotor rhinitis and season-dependent allergic rhinitis, eg hay fever
  • the compounds according to the invention are suitable for the treatment and / or prophylaxis of fibrotic disorders of the internal organs such as, for example, the lung, the heart, the kidney, the bone marrow and in particular the liver, as well as dermatological fibroses and fibrotic disorders of the eye.
  • fibrotic disorders includes in particular the following terms: liver fibrosis, liver cirrhosis, pulmonary fibrosis, endomyocardial fibrosis, cardiomyopathy, nephropathy, glomerulonephritis, interstitial renal fibrosis, fibrotic damage as a result of diabetes, bone marrow fibrosis and similar fibrotic disorders, scleroderma, morphea, keloids, Hypertrophic scarring (also after surgical procedures), nevi, diabetic retinopathy and proliferative vitroretinopathy.
  • the compounds according to the invention can also be used for the treatment and / or prophylaxis of dyslipidemias (hypercholesterolemia, hypertriglyceridemia, elevated concentrations of postprandial plasma triglycerides, hypoalphalipoproteinemia, combined hyperlipidemias) metabolic diseases (type 1 and type 2 diabetes, metabolic syndrome, Overweight, obesity), nephropathy and neuropathy), cancers (skin cancer, brain tumors, breast cancer, bone marrow tumors, leukemia, liposarcoma, carcinomas of the gastrointestinal tract, liver, pancreas, lung, kidney, ureter, prostate and genital tract, and malignant - -
  • dyslipidemias hypercholesterolemia, hypertriglyceridemia, elevated concentrations of postprandial plasma triglycerides, hypoalphalipoproteinemia, combined hyperlipidemias
  • metabolic diseases type 1 and type 2 diabetes, metabolic syndrome, Overweight, obesity
  • nephropathy and neuropathy cancers (skin cancer, brain
  • Tumors of the lymphoproliferative system e.g. Diseases of the gastrointestinal tract and the abdomen (glossitis, gingivitis, periodontitis, esophagitis, eosinophilic gastroenteritis, mastocytosis, Crohn's disease, colitis, proctitis, pruritis ani, diarrhea, celiac disease, hepatitis, chronic hepatitis, liver fibrosis, Hodgkin's and non-Hodgkin's lymphoma) Liver cirrhosis, pancreatitis and cholecystitis), skin diseases (allergic skin diseases, psoriasis, acne, eczema, eczema, multiple forms of dermatitis, as well as keratitis, bullosis, vasculitis, cellulitis, panniculitis, lupus erythematosus, erythema, lymphoma, skin cancer, Sweet
  • the compounds of the formula (I) according to the invention are furthermore suitable for the treatment and / or prophylaxis of ophthalmological diseases such as, for example, glaucoma, normotensive glaucoma, ocular hypertension and combinations thereof, age-related macular degeneration (AMD), dry or non-exudative AMD, moist or exudative or neovascular AMD, choroidal neovascularization (CNV), retinal detachment, diabetic retinopathy, atrophic retinal pigment epithelium (RPE), hypertrophic retinal pigment epithelium (RPE), diabetic macular edema, diabetic retinopathy, retinal vein occlusion, retinal vein cortical occlusion, macular edema, macular edema due to retinal vein occlusion, Angiogenesis on the front of the eye such as corneal angiogenesis for example after keratitis, corneal transplantation or keratoplasty, corneal
  • the compounds according to the invention are particularly suitable for the treatment and / or prophylaxis of acute heart failure, right heart failure, left heart failure, global insufficiency, diabetic heart failure, heart failure with preserved systolic pump function (HFpEF), diastolic heart failure, heart failure with reduced systolic pump function (HFrEF systolic heart failure), coronary heart disease, stable and unstable angina pectoris, myocardial ischemia, acute coronary syndrome, NSTEMI (non-ST segment elevation myocardial infarction), STEMI (ST segment elevation infarct), - 7 - ischemic myocardial injury, myocardial infarction, coronary microvascular dysfunction, microvascular obstruction, no-reflow phenomenon, transient and ischemic attacks, ischemic and hemorrhagic stroke, peripheral and cardiovascular diseases, peripheral circulatory disorders, peripheral arterial disease, primary and secondary Raynaud's syndrome, Microcirculatory disorders,
  • the present invention furthermore relates to the compounds according to the invention for use in a method for the treatment and / or prophylaxis of acute heart failure, coronary heart disease, myocardial infarction, microvascular dysfunction, peripheral arterial occlusive disease, renal insufficiency and nephropathies.
  • the treatment or the prevention of a disease, a disease, a disease, an injury or a health disorder can be partial or complete.
  • Another object of the present invention is thus the use of the compounds of the invention for the treatment and / or prevention of diseases, in particular the aforementioned diseases.
  • Another object of the present invention is the use of the compounds of the invention for the manufacture of a medicament for the treatment and / or prevention of diseases, in particular the aforementioned diseases.
  • Another object of the present invention is a pharmaceutical composition containing at least one of the compounds of the invention, for the treatment and / or prevention of diseases, in particular the aforementioned diseases.
  • Another object of the present invention is the use of the compounds of the invention in a method for the treatment and / or prevention of diseases, in particular the aforementioned diseases.
  • Another object of the present invention is a method for the treatment and / or prevention of diseases, in particular the aforementioned diseases, using an effective amount of at least one of the compounds of the invention.
  • the compounds according to the invention can be used alone or as needed in combination with one or more other pharmacologically active substances, as long as this combination does not lead to undesired and unacceptable side effects.
  • Another object of the present invention are therefore pharmaceutical compositions containing at least one of the compounds of the invention and one or more other active ingredients, in particular for the treatment and / or prevention of the aforementioned diseases.
  • Suitable combination active ingredients for this purpose are by way of example and preferably mentioned:
  • Antihypertensive agents by way of example and by way of preference from the group of calcium antagonists, angiotensin AII antagonists, ACE inhibitors, NEP inhibitors, vasopeptidase inhibitors, and combinations of these, e.g. Sacubitril / valsartan, nicorandil, endothelin antagonists, thromboxane A2 antagonists, renin inhibitors, alpha-receptor blockers, beta-receptor blockers, mineralocorticoid receptor antagonists, rho-kinase inhibitors, diuretics, and other vasoactive agents, e.g. Adenosine and adenosine receptor agonists.
  • angiotensin AII antagonists e.g. Sacubitril / valsartan, nicorandil, endothelin antagonists, thromboxane A2 antagonists, renin inhibitors, alpha-receptor blockers, beta-receptor
  • Antiarrhythmic agents such as, and preferably, sodium channel blockers, beta-blockers, potassium channel blockers, calcium channel blockers, if-channel blockers, digitalis, parasympatholytics (vagolytics), sympathomimetics, and other antiarrhythmic agents, e.g. Adenosine, adenosine receptor agonists and vernakalant;
  • Positive-inotropic agents e.g. Cardiac glycosides (digoxin), beta-adrenergic and dopaminergic agonists such as isoprenaline, epinephrine, norepinephrine, dopamine or dobutamine and serelaxin;
  • beta-adrenergic and dopaminergic agonists such as isoprenaline, epinephrine, norepinephrine, dopamine or dobutamine and serelaxin;
  • Vasopressin receptor antagonists such as, and preferably, Conivaptan, Tolvaptan, Lixivaptan, Mozavaptan, Satavaptan, SR-121463, RWJ 676070 or BAY 86-8050, as well as those described in WO 2010/105770, WO2011 / 104322 and WO 2016/071212 Links;
  • Natriuretic peptides such as, for example and preferably, atrial natriuretic peptide (ANP), natriuretic peptide type B (BNP, nesiritide) natriuretic peptide type C (CNP) or urodilatin;
  • ANP atrial natriuretic peptide
  • BNP natriuretic peptide type B
  • CNP natriuretic peptide type C
  • urodilatin urodilatin
  • Cardiac myosin activators such as and preferably e.g. Omecamtiv Mecarbil (CK-1827452);
  • Calcium sensitizers such as and preferably levosimendan - -
  • Compounds affecting the energy metabolism of the heart such as by way of example and preferably etomoxir, dichloroacetate, ranolazine or trimetazidine, full or partial adenosine AI receptor agonists such as GS-9667 (formerly known as CVT-3619), capadenosone and neladenosone;
  • cGMP cyclic guanosine monophosphate
  • cAMP cyclic adenosine monophosphate
  • PDE phosphodiesterases
  • Antithrombotic agents by way of example and preferably from the group of platelet aggregation-inhibiting substances (platelet aggregation inhibitors, platelet aggregation inhibitors), anticoagulants or anticoagulant substances or profibrinolytic substances;
  • Bronchodilator agents by way of example and preferably from the group of beta-adrenergic receptor agonists, in particular albuterol, isoproterenol, metaproterenol, terbutaline, formoterol or salmeterol, or from the group of anticholinergics, in particular ipratropium bromide;
  • Anti-inflammatory agents by way of example and preferably from the group of glucocorticoids, in particular prednisone, prednisolone, methylprednisolone, triamcinolone, dexamethasone,
  • NSAIDs non-steroidal anti-inflammatory drugs
  • Receptor antagonists such as CCR1, 2 and / or 5 inhibitors; ⁇ Fat metabolism-altering agents, by way of example and preferably from the group of thyroid receptor agonists, cholesterol synthesis inhibitors such as by way of example and preferably HMG-CoA reductase or squalene synthesis inhibitors, ACAT inhibitors, CETP inhibitors, MTP inhibitors, PPAR inhibitors alpha, PPAR gamma and / or PPAR-8 agonists, cholesterol absorption inhibitors, lipase inhibitors, polymeric bile acid adsorbers, bile acid reabsorption inhibitors, and lipoprotein (a) antagonists.
  • ⁇ Fat metabolism-altering agents by way of example and preferably from the group of thyroid receptor agonists, cholesterol synthesis inhibitors such as by way of example and preferably HMG-CoA reductase or squalene synthesis inhibitors, ACAT inhibitors, CETP inhibitors, MTP inhibitors, PPAR inhibitors alpha, PP
  • the signal transduction cascade inhibiting compounds for example and preferably from the group of kinase inhibitors, in particular from the group of tyrosine kinase and / or serine / threonine kinase inhibitors;
  • MMPs matrix metalloproteases
  • Stromelysin, collagenases, gelatinases and aggrecanases in particular MMP-1, MMP-3, MMP-8, MMP-9, MMP-10, MMP-11 and MMP-13
  • MMP-12 metallo-elastase
  • HNE neutrophil elastase
  • organic nitrates and NO donors such as sodium nitroprusside, nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, molsidomine or SIN-1, and inhaled NO;
  • NO-independent, but heme-dependent, stimulators of soluble guanylate cyclase in particular the compounds described in WO 00/06569, WO 02/42301, WO 03/095451, WO 2011/147809, WO2014 / 068099 and 2014/131760;
  • sGC modulators such as by way of example and preferably riociguat, cinaciguat or vericiguat
  • Prostacyclin analogs such as by way of example and preferably iloprost, beraprost, treprostinil or epoprostenol
  • soluble epoxide hydrolase such as NN'-dicyclohexylurea, 12- (3-adamantan-1-yl-ureido) -dodecanoic acid or 1-adamantan-1-yl-3- ⁇ 5- [2- (2-ethoxyethoxy) ethoxy] pentyl ⁇ urea;
  • Glucose metabolism-modifying agents such as insulins, biguanides, thiazolidinediones, sulfonylureas, acarbose, DPP4 inhibitors, GLP-1 analogs or SGLT-1 inhibitors;
  • Neurotransmitter-modulating agents such as tricyclic antidepressants such as amitriptyline and imipramine, monooxidase (MAO) inhibitors such as moclobemide, serotonin norepinephrine reuptake inhibitors such as venlaflaxin, selective serotonin reuptake inhibitors such as sertraline or noradrenaline serotonin selective antidepressants such as mirtazepine.
  • tricyclic antidepressants such as amitriptyline and imipramine
  • MAO monooxidase
  • serotonin norepinephrine reuptake inhibitors such as venlaflaxin
  • selective serotonin reuptake inhibitors such as sertraline or noradrenaline serotonin selective antidepressants such as mirtazepine.
  • tranquilizers such as short-acting or medium-acting benzodiazepines.
  • antihypertensive agents are preferably compounds from the group of calcium antagonists, angiotensin AII antagonists, ACE inhibitors, endothelin antagonists, TXA2 antagonists, renin inhibitors, alpha-receptor blockers, beta-receptor blockers, mineralocorticoid Receptor antagonists, Rho-kinase inhibitors and diuretics understood.
  • the compounds according to the invention are administered in combination with a calcium antagonist, such as, by way of example and by way of preference, nifedipine, amlodipine, verapamil or diltiazem.
  • a calcium antagonist such as, by way of example and by way of preference, nifedipine, amlodipine, verapamil or diltiazem.
  • the compounds according to the invention are used in combination with an angiotensin AII antagonist, such as by way of example and preferably losartan, candesartan, valsartan, telmisartan or embursatan, irbesartan, olmesartan, eprosartan or acylsartan or a dual angiotensin AII antagonist / NEP inhibitor, such as, and preferably, Entresto (LCZ696, Valsartan / Sacubitril).
  • an angiotensin AII antagonist such as by way of example and preferably losartan, candesartan, valsartan, telmisartan or embursatan, irbesartan, olmesartan, eprosartan or acylsartan or a dual angiotensin AII antagonist / NEP inhibitor, such as, and preferably, Entresto (LCZ696, Valsartan / Sacubitril).
  • the compounds according to the invention are administered in combination with an ACE inhibitor, such as by way of example and preferably enalapril, captopril, lisinopril, ramipril, delapril, fosinopril, quinopril, perindopril or trandopril.
  • an ACE inhibitor such as by way of example and preferably enalapril, captopril, lisinopril, ramipril, delapril, fosinopril, quinopril, perindopril or trandopril.
  • the compounds according to the invention are administered in combination with an endothelin antagonist such as, by way of example and by way of preference, bosentan, darusentan, ambrisentan, avosentan, macitentan, atrasentan or sitaxsentan.
  • an endothelin antagonist such as, by way of example and by way of preference, bosentan, darusentan, ambrisentan, avosentan, macitentan, atrasentan or sitaxsentan.
  • the compounds of the invention are used in combination with a thromboxane A2 antagonist such as, for example, and preferably Seratrodast, or KP-496.
  • a thromboxane A2 antagonist such as, for example, and preferably Seratrodast, or KP-496.
  • the compounds of the invention are administered in combination with a renin inhibitor, such as by way of example and preferably aliskiren, SPP-600 or SPP-800.
  • the compounds according to the invention are administered in combination with an alpha-1-receptor blocker, such as by way of example and preferably prazosin. - -
  • the compounds according to the invention are used in combination with a beta-receptor blocker, such as by way of example and preferably propranolol, atenolol, timolol, pindolol, alprenolol, oxprenolol, penbutolol, bupranolol, metipranolol, nadolol, mepindolol, carazalol, sotalol, Metoprolol, betaxolol, celiprolol, bisoprolol, carteolol, esmolol, labetalol, carvedilol, adaprolol, landiolol, nebivolol, epanolol or bucindolol.
  • a beta-receptor blocker such as by way of example and preferably propranolol, atenolol, timolol
  • the compounds according to the invention are administered in combination with a mineralocorticoid receptor antagonist, such as, by way of example and by way of preference, spironolactone, eplerenone or finerenone.
  • a mineralocorticoid receptor antagonist such as, by way of example and by way of preference, spironolactone, eplerenone or finerenone.
  • the compounds according to the invention are used in combination with a rho-kinase inhibitor such as, for example and preferably, Fasudil, Y-27632, SLx-2119, BF-66851, BF-66852, BF-66853, KI-23095, SB-772077, GSK-269962A or BA-1049.
  • a rho-kinase inhibitor such as, for example and preferably, Fasudil, Y-27632, SLx-2119, BF-66851, BF-66852, BF-66853, KI-23095, SB-772077, GSK-269962A or BA-1049.
  • the compounds of the present invention are administered in combination with a diuretic such as and furosemide, torasemide, bumetanide and piretanide with potassium sparing diuretics such as amiloride and triamterene and thiazide diuretics such as hydrochlorothiazide, chlorthalidone, xipamide, and indapamide ,
  • a diuretic such as and furosemide, torasemide, bumetanide and piretanide
  • potassium sparing diuretics such as amiloride and triamterene and thiazide diuretics
  • Antithrombotic agents are preferably understood as meaning compounds from the group of platelet aggregation inhibitors, anticoagulants or profibrinolytic substances.
  • the compounds according to the invention are used in combination with platelet aggregation-inhibiting substances (platelet aggregation inhibitors, platelet aggregation inhibitors) such as, for example and preferably, aspirin, clopidogrel, prasugrel, ticlopidine, ticagrelor, cangrelor, elinogrel, tirofiban, PAR-1 antagonists such as, for example, vorapaxar.
  • platelet aggregation inhibitors such as, for example and preferably, aspirin, clopidogrel, prasugrel, ticlopidine, ticagrelor, cangrelor, elinogrel, tirofiban, PAR-1 antagonists such as, for example, vorapaxar.
  • PAR-4 antagonists EP3 antagonists such as DG041 or adenosine transporter inhibitors such as dipyridamole administered.
  • the compounds according to the invention are administered in combination with a GPIIb / IIIa antagonist, such as, by way of example and by way of preference, tirofiban or abciximab.
  • a GPIIb / IIIa antagonist such as, by way of example and by way of preference, tirofiban or abciximab.
  • the compounds according to the invention are administered in combination with a thrombin inhibitor, such as by way of example and preferably dabigatran, ximelagatran, melagatran, bivalirudin or clexan.
  • the compounds according to the invention are used in combination with a factor Xa inhibitor, such as by way of example and preferably rivaroxaban, apixaban, edoxaban (DU-176b), darexaban, betrixaban otamixaban, letaxaban, fidexaban, razaxaban, fondaparinux, idraparinux, and Thrombin inhibitors such as by way of example and preferably dabigatran, dual thrombin / factor Xa inhibitors such as exemplified and preferably Tanogitran or factor XIa inhibitors administered.
  • a factor Xa inhibitor such as by way of example and preferably rivaroxaban, apixaban, edoxaban (DU-176b), darexaban, betrixaban otamixaban, letaxaban, fidexaban, razaxaban, fondaparinux, idraparinux, and Thromb
  • the compounds according to the invention are used in combination with heparin or a low molecular weight (LMW) heparin derivative such as tinzaparin, certoparin, parnaparin, nadroparin, ardeparin, enoxaparin, reviparin, dalteparin, danaparoid, semuloparin (AVE 5026 ), Adomiparin (Ml 18) and EP-42675 / ORG42675.
  • LMW low molecular weight
  • the compounds according to the invention are administered in combination with a vitamin K antagonist, such as by way of example and preferably coumarins such as Macumar or phenprocoumon.
  • a vitamin K antagonist such as by way of example and preferably coumarins such as Macumar or phenprocoumon.
  • the compounds of the invention are administered in combination with per fibrino lyric compounds such as by way of example and preferably streptokinase, urokinase or plasminogen activator.
  • lipid metabolizing agents are preferably compounds from the group of CETP inhibitors, thyroid receptor agonists, cholesterol synthesis inhibitors such as HMG-CoA reductase or squalene synthesis inhibitors, ACAT inhibitors, MTP inhibitors, PPAR-alpha, PPAR gamma and / or PPAR-8 agonists, cholesterol absorption inhibitors, polymeric bile acid adsorbers, bile acid reabsorption inhibitors, lipase inhibitors and lipoproteins antagonists understood.
  • cholesterol synthesis inhibitors such as HMG-CoA reductase or squalene synthesis inhibitors
  • ACAT inhibitors such as HMG-CoA reductase or squalene synthesis inhibitors
  • MTP inhibitors MTP inhibitors
  • PPAR-alpha PPAR-alpha
  • PPAR gamma and / or PPAR-8 agonists cholesterol absorption inhibitors
  • polymeric bile acid adsorbers bile acid
  • the compounds of the invention are administered in combination with a CETP inhibitor such as, by way of example and by way of preference, torcetrapib (CP-529 414), anacetrapib, JJT-705 or CETP vaccine (Avant).
  • a CETP inhibitor such as, by way of example and by way of preference, torcetrapib (CP-529 414), anacetrapib, JJT-705 or CETP vaccine (Avant).
  • the compounds of the invention are administered in combination with a thyroid receptor agonist such as, by way of example and by way of preference, D-thyroxine, 3,5,3'-triiodothyronine (T3), CGS 23425 or axitirome (CGS 26214).
  • a thyroid receptor agonist such as, by way of example and by way of preference, D-thyroxine, 3,5,3'-triiodothyronine (T3), CGS 23425 or axitirome (CGS 26214).
  • the compounds according to the invention are administered in combination with an HMG-CoA reductase inhibitor from the class of statins, such as by way of example and preferably lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, rosuvastatin or pitavastatin.
  • statins such as by way of example and preferably lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, rosuvastatin or pitavastatin.
  • the compounds of the invention are administered in combination with a squalene synthesis inhibitor such as, for example and preferably, BMS-188494 or TAK-475.
  • a squalene synthesis inhibitor such as, for example and preferably, BMS-188494 or TAK-475.
  • the compounds according to the invention are administered in combination with an ACAT inhibitor, such as by way of example and preferably avasimibe, melinamide, pactimibe, eflucimibe or SMP-797.
  • an ACAT inhibitor such as by way of example and preferably avasimibe, melinamide, pactimibe, eflucimibe or SMP-797.
  • the compounds according to the invention are administered in combination with an MTP inhibitor such as, for example and preferably, implitapide, BMS-201038, R-103757 or JTT-130.
  • an MTP inhibitor such as, for example and preferably, implitapide, BMS-201038, R-103757 or JTT-130.
  • the compounds of the invention are administered in combination with a PPAR-gamma agonist such as, by way of example and by way of preference, pioglitazone or rosiglitazone.
  • the compounds according to the invention are administered in combination with a PPAR-8 agonist, such as by way of example and preferably GW 501516 or BAY 68-5042.
  • the compounds according to the invention are administered in combination with a cholesterol absorption inhibitor, such as by way of example and preferably ezetimibe, tiqueside or pamaqueside.
  • a cholesterol absorption inhibitor such as by way of example and preferably ezetimibe, tiqueside or pamaqueside.
  • the compounds according to the invention are administered in combination with a lipase inhibitor, such as, for example and preferably, orlistat.
  • a lipase inhibitor such as, for example and preferably, orlistat.
  • the compounds of the invention are administered in combination with a polymeric bile acid adsorbent such as, by way of example and by way of preference, cholestyramine, colestipol, colesolvam, cholesta gel or colestimide.
  • a polymeric bile acid adsorbent such as, by way of example and by way of preference, cholestyramine, colestipol, colesolvam, cholesta gel or colestimide.
  • ASBT IBAT
  • AZD-7806 S-8921
  • AK-105 AK-105
  • BARI-1741 AK-105
  • SC-435 SC-635.
  • the compounds according to the invention are administered in combination with a lipoprotein (a) antagonist, such as, by way of example and by way of preference, gemcabene calcium (CI-1027) or nicotinic acid.
  • a lipoprotein (a) antagonist such as, by way of example and by way of preference, gemcabene calcium (CI-1027) or nicotinic acid.
  • Active substances which inhibit signal transduction cascades are preferably compounds from the group of tyrosine kinase inhibitors and / or serine / threonine kinase inhibitors.
  • the compounds according to the invention are administered in combination with a kinase inhibitor, such as by way of example and preferably bortezomib, canertinib, erlotinib, gefitinib, imatinib, lapatinib, lestaurtinib, lonafarnib, nintedanib, dasatinib, nilotinib, bosutinib, axitinib, telatinib, Imatinib, brivanib, pazopanib, pegaptinib, pelitinib, semaxanib, sorafenib, regorafenib, sunitinib, tandutinib, tipifarnib, vatalanib, fasudil, lonidamine, leflunomide, BMS-3354825 or Y-27632.
  • a kinase inhibitor such as by way of
  • Agents that modulate glucose metabolism are preferably compounds from the group of insulins, a sulfonylurea, acarbose, DPP4 inhibitors, GLP-1 analogs or SGLT-1 inhibitor.
  • Agents that modulate neurotransmitters are preferably understood to be compounds from the group of tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, serotonin norepinephrine reuptake inhibitors (SNRs) and norepinephrine serotonin-selective antidepressants (NaSSa).
  • MAO monoamine oxidase
  • SNRs serotonin norepinephrine reuptake inhibitors
  • NaSSa norepinephrine serotonin-selective antidepressants
  • the compounds according to the invention are administered in combination with a tricyclic antidepressant such as, by way of example and by way of preference, amitryptiline or imipramine.
  • a tricyclic antidepressant such as, by way of example and by way of preference, amitryptiline or imipramine.
  • the compounds according to the invention are used in combination with monoamine oxidase (MAO) inhibitors, by way of example and preferably mocolobemide
  • MAO monoamine oxidase
  • the compounds according to the invention are administered in combination with a selective serotonin norepinephrine reuptake inhibitor (SNRI), by way of example and preferably venlafaxine.
  • SNRI selective serotonin norepinephrine reuptake inhibitor
  • the compounds of the invention are administered in combination with a selective serotonin reuptake inhibitor such as sertraline.
  • the compounds according to the invention are administered in combination with a norepinephrine serotonin-selective antidepressant (NaSSa) such as by way of example and preferably mirtazepine.
  • NaSSa norepinephrine serotonin-selective antidepressant
  • Agents having analgesic, anxiolytic or sedative properties are preferably understood to be compounds from the class of opiates and benzodiazepines. - -
  • the compounds according to the invention are administered in combination with an opiate such as, for example and preferably, morphine or sufentanil or fentanyl.
  • an opiate such as, for example and preferably, morphine or sufentanil or fentanyl.
  • the compounds according to the invention in combination with a benzodiazepine are exemplified and preferably midazolam or diazepam.
  • drugs that enhance the synthesis of cGMP such as sGC modulators, preferably compounds that stimulate or activate soluble guanylate cyclase are understood.
  • the compounds according to the invention are administered in combination with sGC modulators, such as by way of example and preferably riociguat, cinaciguat or vericiguat.
  • the compounds of the invention are used in combination with full or partial adenosine AI receptor agonists such as GS-9667 (formerly known as CVT-3619), capadenosone and neladenosone or mitochondrial function / ROS production agents, such as Bendavia / Elamipritide administered;
  • the compounds according to the invention are administered in combination with a TGFbeta antagonist, such as by way of example and preferably pirfenidone or fresolimumab.
  • the compounds according to the invention are administered in combination with a TNFalpha antagonist, such as by way of example and preferably adalimumab.
  • the compounds according to the invention are administered in combination with HIF-PH inhibitors, such as by way of example and preferably Molidustat or Roxadustat.
  • the compounds according to the invention are used in combination with a serotonin receptor antagonist, such as by way of example and preferably PRX-08066.
  • HMG CoA reductase inhibitors include fat metabolism-altering agents, glucose metabolism-altering agents, and anxiety and pain-relieving drugs such as benzodiazepines and opiates.
  • the present invention further relates to medicaments, and pharmaceutical compositions containing at least one compound of the invention, usually together with one or more inert, non-toxic, pharmaceutically suitable excipients, and to their use for the purposes mentioned above.
  • the compounds according to the invention can act systemically and / or locally.
  • they may be applied in a suitable manner, e.g. oral, parenteral, pulmonary, nasal, sublingual, lingual, buccal, rectal, vaginal, dermal, transdermal, conjunctival, otic or as an implant or stent.
  • the compounds according to the invention can be administered in suitable administration forms.
  • Parenteral administration can be accomplished by bypassing a resorption step (e.g., intravenously, intraarterially, intracardially, intraspinal, or intralumbar) or by resorting to absorption (e.g., intramuscularly, subcutaneously, intracutaneously, percutaneously, intravitreally, or intraperitoneally).
  • a resorption step e.g., intravenously, intraarterially, intracardially, intraspinal, or intralumbar
  • absorption e.g., intramuscularly, subcutaneously, intracutaneously, percutaneously, intravitreally, or intraperitoneally.
  • parenteral administration are suitable as application forms u.a. Injection and infusion preparations in the form of solutions, suspensions, emulsions, lyophilisates or sterile powders.
  • inhalant medicines including powder inhalers, nebulizers
  • nasal drops solutions, sprays; lingual, sublingual or buccal tablets to be applied, films / wafers or capsules, suppositories, eye drops, eye ointments, eye baths, ocular inserts, ear drops, sprays, powders, rinses, tampons, vaginal capsules, aqueous suspensions (lotions, shake mixtures), lipophilic suspensions, emulsions, microemulsions, ointments, creams, transdermal therapeutic systems (such as patches), milk, pastes, foams, scattering powders, implants or stents.
  • inhalant medicines including powder inhalers, nebulizers
  • nasal drops solutions, sprays
  • lingual, sublingual or buccal tablets to be applied, films / wafers or capsules, suppositories, eye drops, eye ointments, eye baths, ocular inserts, ear drops, spray
  • the compounds according to the invention can be converted into the stated administration forms. This can be done in a conventional manner by mixing with pharmaceutically suitable excipients.
  • These adjuvants include, among others.
  • Fillers and carriers for example cellulose, microcrystalline cellulose such as Avicel®, lactose, mannitol, starch, calcium phosphates such as Di-Cafos®),
  • Ointment bases for example vaseline, paraffins, triglycerides, waxes, wool wax, wool wax alcohols, lanolin, hydrophilic ointment, polyethylene glycols
  • vaseline paraffins, triglycerides, waxes, wool wax, wool wax alcohols, lanolin, hydrophilic ointment, polyethylene glycols
  • Suppository bases for example polyethylene glycols, cocoa butter, hard fat
  • Solvents e.g., water, ethanol, isopropanol, glycerol, propylene glycol, medium chain triglycerides, fatty oils, liquid polyethylene glycols, paraffins
  • solvents e.g., water, ethanol, isopropanol, glycerol, propylene glycol, medium chain triglycerides, fatty oils, liquid polyethylene glycols, paraffins
  • Surfactants, emulsifiers, dispersing or wetting agents for example sodium dodecylsulfate, lecithin, phospholipids, fatty alcohols such as Lanette®, sorbitan fatty acid esters such as Span®, polyoxyethylene sorbitan fatty acid esters such as Tween®, polyoxyethylene fatty acid glycerides such as Cremophor®, polyoxethylene fatty acid esters , Polyoxyethylene fatty alcohol ethers, glycerol fatty acid esters, poloxamers such as Pluronic®),
  • dispersing or wetting agents for example sodium dodecylsulfate, lecithin, phospholipids, fatty alcohols such as Lanette®, sorbitan fatty acid esters such as Span®, polyoxyethylene sorbitan fatty acid esters such as Tween®, polyoxyethylene fatty acid glycerides such as Cremophor®, polyoxethylene fatty acid esters , Poly
  • Buffer substances and acids and bases for example phosphates, carbonates, citric acid, acetic acid, hydrochloric acid, sodium hydroxide solution, ammonium carbonate, trometamol, triethanolamine
  • acids and bases for example phosphates, carbonates, citric acid, acetic acid, hydrochloric acid, sodium hydroxide solution, ammonium carbonate, trometamol, triethanolamine
  • Isotonizing agents for example, glucose, sodium chloride
  • Adsorbents for example finely divided silicas
  • viscosity-increasing agents for example gelling agents, thickeners or binders
  • binders for example polyvinylpyrrolidone, methylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, carboxymethylcellulose sodium, starch, carbomers, polyacrylic acids such as Carbopol®, alginates, gelatin
  • binders for example polyvinylpyrrolidone, methylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, carboxymethylcellulose sodium, starch, carbomers, polyacrylic acids such as Carbopol®, alginates, gelatin
  • Disintegrants e.g., modified starch, carboxymethylcellulose sodium, sodium starch glycolate such as Explotab®, cross-linked polyvinylpyrrolidone, croscarmellose sodium such as AcDiSol®
  • modified starch carboxymethylcellulose sodium, sodium starch glycolate such as Explotab®, cross-linked polyvinylpyrrolidone, croscarmellose sodium such as AcDiSol®
  • Flow regulators, lubricants, lubricants and mold release agents for example magnesium stearate, stearic acid, talc, finely divided silicas such as Aerosil®), - -
  • Coating agents for example sugar, Schellac
  • film-forming agents for rapidly or modified dissolving films or diffusion membranes for example polyvinylpyrrolidones such as Kollidon®, polyvinyl alcohol, hydroxypropylmethylcellulose, hydroxypropylcellulose, ethylcellulose, hydroxypropylmethylcellulose phthalate, cellulose acetate, cellulose acetate phthalate, polyacrylates, polymethacrylates such as Eudragit®) .
  • Capsule materials e.g., gelatin, hydroxypropyl methylcellulose
  • Synthetic polymers for example polylactides, polyglycolides, polyacrylates, polymethacrylates such as Eudragit®, polyvinylpyrrolidones such as Kollidon®, polyvinyl alcohols, polyvinyl acetates, polyethylene oxides, polyethylene glycols and their copolymers and block copolymers), plasticizers (for example polyethylene glycols, propylene glycol, glycerol, triacetin, triacetyl citrate , Dibutyl phthalate),
  • plasticizers for example polyethylene glycols, propylene glycol, glycerol, triacetin, triacetyl citrate , Dibutyl phthalate
  • Stabilizers e.g., antioxidants such as ascorbic acid, ascorbyl palmitate, sodium ascorbate, butylhydroxyanisole, butylhydroxytoluene, propyl gallate
  • preservatives e.g., parabens, sorbic acid, thiomersal, benzalkonium chloride, chlorhexidine acetate, sodium benzoate
  • Dyes e.g., inorganic pigments such as iron oxides, titanium dioxide
  • Flavors, sweeteners, flavor and / or smell remedies • Flavors, sweeteners, flavor and / or smell remedies.
  • the iv application is particularly preferred, in particular in physiological saline solution.
  • compositions containing at least one compound of the invention are pharmaceutical compositions containing at least one compound of the invention, usually together with one or more pharmaceutically suitable excipients, and their use according to the present invention.
  • the dosage is about 0.01 to 100 mg / kg, preferably about 0.01 to 20 mg / kg and most preferably 0.1 to 10 mg / kg of body weight.
  • the amount is generally about 0.1 to 50 mg per inhalation. - -
  • Method 1 Instrument: Waters Single Quad MS System; Instrument Waters UPLC Acquity; Column: Waters BEH C18 1.7 ⁇ 50 x 2.1 mm; Eluent A: 1 1 water + 1.0 mL (25% ammonia) / L, eluent B: 1 L acetonitrile; Gradient: 0.0 min 92% A -> 0.1 min 92% A -> 1.8 min 5% A -> 3.5 min 5% A; Oven: 50 ° C; Flow: 0.45 mL / min; UV detection: 210 nm (208-400 nm).
  • Method 2 Device Type MS: Thermo Scientific FT-MS; Device type UHPLC +: Thermo Scientific UltiMate 3000; Column: Waters, HSST3, 2.1 x 75 mm, C18 1.8 ⁇ ; Eluent A: 1 liter of water + 0.01% of formic acid; Eluent B: 1 liter acetonitrile + 0.01% formic acid; Gradient: 0.0 min 10% B -> 2.5 min 95% B -> 3.5 min 95% B; Oven: 50 ° C; Flow: 0.90 ml / min; UV detection: 210 nm / Optimum Integration Path 210-300 nm. - -
  • Method 3 Instrument: Waters ACQUITY SQD UPLC System; Column: Waters Acquity UPLC HSS T3 1.8 ⁇ 50 x 1 mm; Eluent A: 1 l of water + 0.25 ml of 99% formic acid, eluent B: 1 l of acetonitrile + 0.25 ml of 99% formic acid; Gradient: 0.0 min 90% A -> 1.2 min 5% A -> 2.0 min 5% A Furnace: 50 ° C; Flow: 0.40 ml / min; UV detection: 208-400 ⁇ m.
  • Method 4 Instrument: Agilent MS Quad 6150; HPLC: Agilent 1290; Column: Waters Acquity UPLC HSS T3 1.8 ⁇ 50 x 2.1 mm; Eluent A: 1 l of water + 0.25 ml of 99% formic acid, eluent B: 1 l of acetonitrile + 0.25 ml of 99% formic acid; Gradient: 0.0 min 90% A -> 0.3 min 90% A-> 1.7 min 5% A -> 3.0 min 5% A Furnace: 50 ° C; Flow: 1.20 ml / min; UV detection: 205-305 nm.
  • Method 5 Device Type MS: ThermoFisherScientific LTQ-Orbitrap-XL; Device type HPLC: Agilent 1200SL; Column: Agilent, POROSHELL 120, 3 x 150 mm, SB - C18 2.7 ⁇ ; Eluent A: 1 liter of water + 0.1%) trifluoroacetic acid; Eluent B: 1 liter acetonitrile + 0.1% trifluoroacetic acid; Gradient: 0.0 min 2% B-> 0.3 min 2% B -> 5.0 min 95% B -> 10.0 min 95% B; Oven: 40 ° C; Flow: 0.75 ml / min; UV detection: 210 nm.
  • Method 6 Instrument: Waters ACQUITY SQD UPLC System; Column: Waters Acquity UPLC HSS T3 1.8 ⁇ 50 x 1 mm; Eluent A: 1: 1 water + 0.25 ml 99% formic acid, eluent B: 1: 1 acetonitrile + 0.25 ml 99% formic acid; Gradient: 0.0 min 95% A -> 6.0 min 5% A -> 7.5 min 5% A Oven: 50 ° C; Flow: 0.35 ml / min; UV detection: 210 - 400 nm.
  • prepacked silica gel cartridges such as. B. Biotage SNAP cartridge, KP-Sil ® or KP-NH ® in combination with a Biotage system (SP4 ® or Isolera Four ®) is used.
  • the eluent used are hexane / ethyl acetate or dichloromethane / methanol gradients.
  • the compounds of the invention may be in salt form, for example as trifluoroacetate or formate salt, provided that the compounds of the invention sufficiently basic functionalities contain.
  • a salt can be converted into the corresponding free base by various methods known to those skilled in the art.
  • the exact stoichiometric composition of such a salt as described in US Pat - 5 - respective manufacturing and / or purification process was obtained, usually not known.
  • salt-forming components such as “hydrochloride”, “trifluoroacetate”, “sodium salt” or “x hydrochloric acid”, “x CF 3 COOH”, “x Na + " are therefore not stoichiometric for such salts but solely descriptive of the contained salt-forming components.
  • the secondary amides according to the invention can be present as rotational isomers / isomer mixtures, in particular in NMR investigations.
  • Purity specifications generally refer to corresponding peak integrations in the LC / MS chromatogram, but may additionally have been determined with the aid of the 'H-NMR spectrum. If no purity is specified, it is usually a 100% purity according to automatic peak integration in the LC / MS chromatogram, or purity was not explicitly determined.
  • the intensity of sharp signals correlates with the height of the signals in a printed example of an NMR spectrum in cm and shows the true ratios of the signal intensities compared to other signals. For broad signals, multiple peaks or the center of the signal and their relative intensity can be shown compared to the most intense signal in the spectrum.
  • the lists of the 'H NMR peaks are similar to the classical' H NMR prints and thus usually contain all the peaks listed in a classical NMR interpretation. In addition, they can, like classic 'H-NMR prints solvent signals, signals from stereoisomers of the target compounds, which are also the subject of the invention, and / or show peaks of impurities.
  • the peaks of stereoisomers of the target compounds and / or peaks of impurities usually have on average a lower intensity than the peaks of the target compounds (for example with a purity of> 90%). Such stereoisomers and / or impurities may be typical of the particular preparation process. Their peaks can thus help to detect the reproduction of our manufacturing process by "by-product fingerprints.”
  • An expert calculating the peaks of the target compounds by known methods can isolate the peaks of the target compounds as needed, using additional intensity filters if necessary. This isolation would be similar to peak-picking in classical 1 H NMR interpretation.
  • Methylimidazo [1,2-a] pyridine-7-carboxylate (51.1 g, 290 mmol) was dissolved in 2.5 l of acetonitrile.
  • 1-Iodopyrrolidine-2,5-dione (68.5 g, 304 mmol) was added and the mixture was stirred at room temperature for four days.
  • the reaction was added to 3.5 L of water, adjusted to pH 8 with solid sodium bicarbonate and stirred for 15 minutes.
  • the precipitate was filtered off, washed once with saturated aqueous sodium bicarbonate solution and once with water. Subsequently, the solid was slurried with acetonitrile and sucked dry. The solid was dried in vacuo for two days. A total of 81 g (93% of theory) of the title compound were obtained.
  • Methyl 3-iodoimidazo [1,2-a] pyridine-7-carboxylate (2.80 g, 9.27 mmol) and tetrakis (triphenylphosphine) palladium (0) (536 mg, 463 ⁇ ) were charged in 75 ml of 1,2-dimethoxyethane , and (3,5-dimethyl-1,2-oxazol-4-yl) boronic acid (3.27 g, 23.2 mmol), potassium carbonate (2.56 g, 18.5 mmol) and 37 ml of water were added. The mixture was stirred for 4.5 hours at 75 ° C.
  • Methyl 3-iodoimidazo [1,2-a] pyridine-7-carboxylate (50.0 g, 166 mmol) was initially charged in 2.5 l of N, N-dimethylformamide. (3,5-Dimethyl-1,2-oxazol-4-yl) boric acid (46.7 g, 331 mmol) and cesium fluoride (75.4 g, 497 mmol) were added. Argon was passed through the reaction mixture for 10 minutes. [l, l-Bis (diphenylphosphino) ferrocene] dichloropalladium (II) (13.5 g, 16.6 mmol) was added. The batch was heated to 90 ° C and stirred for three hours.
  • N-Methylpyridin-4-amine (5.00 g, 46.2 mmol) was initially charged in 100 ml of ⁇ , ⁇ -dimethylformamide, 2- (2-bromoethyl) -1H-isoindol-1,3 (2H) -dione (11.7 g, 46.2 mmol) was added and the mixture was stirred at 110 ° C overnight. The precipitated solid was filtered off, washed with methyl tert-butyl ether and dried under high vacuum. There was obtained 13.7 g (82% of theory, 100% purity) of the title compound.
  • Methyl 3-iodoimidazo [1,2-a] pyridine-7-carboxylate 250 mg, 828 ⁇ mol
  • 1,4-dimethyl-5- (4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl) -1H-pyrazole 221 mg, 993 ⁇
  • potassium carbonate 377 mg, 2.73 mmol
  • [l, l-bis (diphenylphosphino) ferrocene] dichloropalladium dichloromethane complex (33.8 mg, 41.4 ⁇ ) was added and stirred overnight at 110 ° C.
  • the reaction mixture was concentrated, the residue taken up in ethyl acetate and washed with water and saturated aqueous sodium chloride solution. The organic phase was dried over sodium sulfate and concentrated. The residue was applied to Isolute and purified by column chromatography (50 g Biotage Snap Cartridge Ultra® Biotage-Isolera-One®, dichloromethane / methanol gradient 2% methanol -20% methanol, flow: 100 ml / min). The product fractions were combined and evaporated. 122 mg (40% of theory, 74% purity) of the title compound were obtained.
  • the product-containing fractions were combined, evaporated and dried under high vacuum. 59 mg (51% of theory, 100% purity) of the title compound were obtained.
  • N-Methylpyridin-4-amine (2.00 g, 18.5 mmol) was initially charged in 20 ml of ⁇ , ⁇ -dimethylformamide, with 2- (3-bromopropyl) -1H-isoindol-1,3 (2H) -dione (4.96 g, 18.5 mmol), and the mixture was stirred at 110 ° C overnight. The precipitated solid was filtered off with suction and washed with methyl tert-butyl ether. The solid was dried under high vacuum. There were obtained 5.62 g (81% of theory, 100% purity) of the title compound.
  • Methyl 3-iodoimidazo [1,2-a] pyridine-7-carboxylate 250 mg, 828 ⁇ mol
  • 1-ethyl-5- (4,4,5,5-tetramethyl-1, 3,2-dioxaborolane) 2-yl) -LH-pyrazole 221 mg, 993 ⁇
  • potassium carbonate 377 mg, 2.73 mmol
  • the product-containing fractions were combined, evaporated and dried under high vacuum. There was obtained 39 mg (26% of theory, 89%) purity of the title compound.
  • Methyl 3-bromoimidazo [1,2-a] pyridine-7-carboxylate 150 mg, 588 ⁇
  • (2-methoxypyridin-3-yl) boronic acid (135 mg, 882 ⁇ )
  • tetrakis (triphenylphosphine) palladium (0 )
  • 2M aqueous sodium carbonate solution 1.5 ml, 2.0 M, 2.9 mmol
  • the product-containing fractions were combined, evaporated and dried under high vacuum. There was obtained 30.5 mg (18% of theory, 100%> purity) of the title compound.
  • N-Methylpyridin-3-amine (1.00 g, 9.25 mmol) was initially charged in 20 ml of ⁇ , ⁇ -dimethylformamide, 2- (3-bromopropyl) -1H-isoindole-1,3'-2H-dione (2.48 g, 9.25 mmol) was added and the mixture was stirred at 110 ° C overnight. The precipitated solid was filtered off with suction, washed with methyl tert-butyl ether and dried under high vacuum. 2.20 g (63% of theory, 100% purity) of the title compound were obtained.
  • N, N-Dimethylpyridin-4-amine (2.00 g, 16.4 mmol) was initially charged in 20 ml of ⁇ , ⁇ -dimethylformamide, 2- (2-bromoethyl) -1H-isoindol-1,3 (2H) -dione (4.16 g , 16.4 mmol) was added and the mixture was stirred at 110 ° C overnight. The precipitated solid was filtered off with suction, washed with methyl tert-butyl ether and dried under high vacuum. There was obtained 5.04 g (82% of theory, 100% purity) of the title compound.
  • N, 3-Dimethylpyridin-4-amine (689 mg, 5.64 mmol) in 12 ml of N, N-dimethylformamide was initially charged under argon, with 2- (2-chloroethyl) -1H-isoindole-1,3 (2H) -dione (1.18 g, 5.64 mmol) and the mixture was stirred at 110 ° C for 48 hours. The precipitated solid was filtered off, washed with diethyl ether and ethyl acetate and dried under high vacuum. 1.14 g (100% pure, 61% of theory) of the title compound were obtained.
  • Example 34A [2- (1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl) ethyl] -2-methyl-4- (methylamino) pyridinium chloride
  • N-ethylpyridin-4-amine 500 mg, 4.09 mmol was initially charged in 10 ml of ⁇ , ⁇ -dimethylformamide, with 2- (2-chloroethyl) -1H-isoindole-1,3 (2H) -dione (858 mg, 4.09 mmol) and the mixture was stirred at 110 ° C over the weekend. The precipitated solid was filtered off with suction, washed with methyl tert-butyl ether and dried under high vacuum. 849 mg (100% purity, 62% of theory) of the title compound were obtained.
  • Example 48A (2-Aminoethyl) -3-methylpyridinium bromide hydrobromide (1: 1: 1)
  • the product fractions were combined, evaporated and the residue dried under high vacuum. 403 mg (70% purity, 33% of theory) of the title compound were obtained.
  • N-methylpyridin-4-amine (1.00 g, 9.25 mmol) was initially charged in 10 ml of ⁇ , ⁇ -dimethylformamide, with 2- (2-chloroethyl) -1H-isoindole-1,3 (2H) -dione (1.94 g, 9.25 mmol), and the mixture was stirred at 110 ° C overnight. The precipitated solid was filtered off, washed with methyl tert-butyl ether and dried under high vacuum. There were obtained 1.99 g (100% purity, 68% of theory) of the title compound.
  • Methyl 3-iodoimidazo [1,2-a] pyridine-7-carboxylate (1.00 g, 3.31 mmol) was charged in 20 mL of tetrahydrofuran, added with lithium hydroxide soln (6.6 mL, 1.0 M, 6.6 mmol), and the mixture was stirred for two hours at room temperature.
  • the tetrahydrofuran was stripped off on a rotary evaporator and the aqueous residue was acidified with 4N hydrochloric acid (pH 3).
  • the precipitated solid was filtered off, washed with acetonitrile and dried under high vacuum. From the filtrate further solid precipitated. This was filtered off, washed with acetonitrile and dried under high vacuum.
  • 3-iodoimidazo [1,2-a] pyridine-7-carboxylic acid (81.4 mg, 283 ⁇ ) was initially charged in 2 ml of dichloromethane, with 2- (aminomethyl) -l-methylimidazo [l, 2-a] pyridine-l iumiodide hydrochloride (1: 1: 1) (92.0 mg, 283 ⁇ ), l - (3-dimethylaminopropyl) -3-ethylcarbodiimidhydrochlorid (81.3 mg, 424 ⁇ ) and 4-dimethylaminopyridine (104 mg, 848 ⁇ ), and the mixture was stirred at room temperature overnight. The precipitated solid was filtered off, washed with dichloromethane and dried under high vacuum. 121 mg (100% purity, 99% of theory) of the title compound were obtained.
  • reaction mixture was grown on Isolute® and purified by silica gel chromatography (28 g Snap Cartridge KP-NH Biotage®, Biotage-Isolera-One®, dichloromethane / methanol gradient 10% methanol to 40%> methanol).
  • silica gel chromatography 28 g Snap Cartridge KP-NH Biotage®, Biotage-Isolera-One®, dichloromethane / methanol gradient 10% methanol to 40%> methanol).
  • Example 64A (2-Ammonioethyl) -4-ethylpyridinium dibromide - -
  • the product-containing fractions were combined, evaporated and lyophilized overnight from acetonitrile / water. 50 mg (56% of theory, 98% purity) of the title compound were obtained.
  • the product-containing fractions were combined, evaporated and lyophilized overnight from acetonitrile / water. 55 mg (62% of theory, 99% purity) of the title compound were obtained.
  • Two product-containing fractions were obtained.
  • the first product-containing fraction was evaporated and lyophilized. There was obtained 167 mg (11%> th., 100%) purity of the title compound.
  • the second product-containing fraction was evaporated, dissolved in 10 ml of acetonitrile / water, treated with 3 ml of formic acid and stirred for 1 h.
  • the product-containing fractions were combined, evaporated and lyophilized. 360 mg (25% of theory, 100% purity) of the title compound were obtained.
  • Step 1 Loading the ion exchanger:
  • Step 2 Exchange Chloride / Formate: 1 - [2- ( ⁇ [3- (3,5-Dimethyl-1,2-oxazol-4-yl) imidazo [1,2-a] pyridin-7-yl] carbonyl ⁇ amino) ethyl] -4- (methylamino) pyridinium chloride (1.00 g, 2.34 mmol) was dissolved in 3 ml of water and passed through the ion exchanger described in step 1. The ion exchanger was washed with 250 ml of water, the combined filtrates were concentrated and dried under high vacuum.
  • the product-containing fractions were combined, evaporated and dried under high vacuum. There were obtained 78 mg (97% of theory, 98% purity) of the title compound.
  • the product-containing fractions were combined, evaporated and dried under high vacuum. There were obtained 35 mg (98%> purity, 42%> D. Th.) Of the title compound.
  • the reaction mixture was concentrated, the residue taken up in methanol, treated with 0.5 ml of formic acid and evaporated over a period of 15 minutes on a rotary evaporator at 50 ° C.
  • the product-containing fractions were combined, evaporated, the residue dissolved in water / acetonitrile and lyophilized. There were obtained 43.3 mg (100% purity, 54% of theory) of the title compound.
  • Example 17 1- [2- ( ⁇ [3- (3,5-Dimethyl-1,2-oxazol-4-yl) imidazo [1,2-a] pyridin-7-yl] carbonyl ⁇ amino) ethyl] - 2-methyl-4- (methylamino) pyridinium formate - -
  • the reaction mixture was concentrated, the residue taken up in methanol, treated with 0.5 ml of formic acid and evaporated over a period of 15 minutes on a rotary evaporator at 50 ° C.
  • the product-containing fractions were combined, evaporated, the residue dissolved in water / acetonitrile and lyophilized. There were obtained 36 mg (100% purity, 45% of theory) of the title compound.
  • the product-containing fractions were combined, evaporated, the residue dissolved in water / acetonitrile and lyophilized. 112 mg (100% purity, 69% of theory) of the title compound were obtained.
  • the product-containing fractions were combined, - - Evaporated, the residue dissolved in water / acetonitrile and lyophilized. 67 mg (99% purity, 79% of theory) of the title compound were obtained.
  • Example 20 [( ⁇ [3- (3,5-Dimethyl-1,2-oxazol-4-yl) imidazo [1,2-a] pyridin-7-yl] carbonyl ⁇ amino) methyl] -1 - methylpyridiniumformiat
  • the product-containing fractions were combined, evaporated and dried under high vacuum. There were obtained 40 mg (100% purity, 55% of theory) of the title compound.
  • the product-containing fractions were combined, evaporated and dried under high vacuum.
  • the product-containing fractions were combined, evaporated and dried under high vacuum.
  • Example 24 [3- ( ⁇ [3- (3,5-Dimethyl-1,2-oxazol-4-yl) imidazo [1,2-a] pyridin-7-yl] carbonyl ⁇ amino) propyl] - 2,4-dimethyl-1H-pyrazole-2-iumformiat - 7 -
  • Lithium 3- (1-isopropyl-1H-pyrazol-5-yl) imidazo [1,2-a] pyridine-7-carboxylate (90.0 mg, 326 ⁇ ) and 1- (2-ammonioethyl) -4- (methylamino ) pyridinium dibromide (112 mg, 358 ⁇ ) were initially charged in 5 ml of dichloromethane, with 1- (3-dimethylaminopropyl) -3-ethylcarbodiimidhydrochlorid (93.7 mg, 489 ⁇ ) and 4-dimethylaminopridine (119 mg, 977 .mu.mol) and the mixture was stirred for 48 hours at room temperature.
  • the product-containing fractions were combined, evaporated and dried under high vacuum. 58 mg (97% purity, 38% of theory) of the title compound were obtained.
  • the product-containing fractions were combined, concentrated and dried under high vacuum. 17 mg (100% purity, 21% of theory) of the title compound were obtained.
  • the product-containing fractions were combined, concentrated and dried under high vacuum. There were obtained 1 1, 7 mg (95% purity, 14% of theory) of the title compound.
  • the product-containing fractions were combined, concentrated and dried under high vacuum. 22 mg (100% purity, 26% of theory) of the title compound were obtained.
  • the product-containing fractions were combined, concentrated and dried under high vacuum. There were obtained 103 mg (99% purity, 57% of theory) of the title compound.
  • the product-containing fractions were combined, concentrated and dried under high vacuum.
  • the residue was purified by preparative TLC (Alox neutral, eluent: dichloromethane / methanol 10: 1). 21.3 mg (90% purity, 32% of theory) of the title compound were obtained.
  • the product fractions were combined, concentrated and lyophilized. There were obtained 39.8 mg (89% purity, 20% of theory) of the title compound.
  • ADRA2B a2B adrenoreceptor
  • the cells were cultured at 37 ° C and 5% CO 2 in Dulbecco's modified Eagle's medium / NUT mix Fl 2 with L-glutamine, which additionally contained 10% (v / v) inactivated fetal calf serum, 1 mM sodium pyruvate, 0.9 mM sodium bicarbonate. 50 U / ml penicillin, 50 ⁇ g / ml streptomycin, 2.5 ⁇ g / ml amphotericin B and 1 mg / ml geneticin. The cells were passaged with Hank's enzyme-free cell dissociation buffer. All cell culture reagents used were from Invitrogen (Carlsbad, USA).
  • Luminescence measurements were performed on white 384-well microtiter plates. 2000 cells / well were plated in a volume of 25 ⁇ and cultured for one day at 30 ° C and 5% CO2 in cell culture medium with coelenterazine (a2B: 5 ug / ml;). Serial dilutions of the test substances (10 ⁇ ) were added to the cells. After 6 minutes norepinephrine was added to the cells (35 ⁇ , final concentration: EC50 - EC80) and the emitted light was allowed to stand for 50 seconds by means of a CCD (Charge-Coupled Device) camera (Hamamatsu Corporation, Shizuoka, Japan) light-tight box measured.
  • CCD Charge-Coupled Device
  • test substances were tested to a maximum concentration of 10 ⁇ .
  • the IC50 values (shown in Table 1) were calculated from the corresponding dose-response curves.
  • a quantification of the coronary blood flow is needed. This can be done by flow probes placed around the coronary vessels. Following intravenous or intracoronary administration of a dilator such as adenosine (i.p., 140 ⁇ g / kg / min for 5 min as an infusion), the increase in coronary blood flow in response to adenosine can be measured using flowmeters.
  • a dilator such as adenosine
  • L-NAME i.d.R. 60 ⁇ g / kg / min at 15 ⁇ / kg / min for 60 min as continuous infusion
  • L-NAME i.a. infused to block the endothelial NO synthase so as to mimic endothelial damage.
  • NAME infusion the blockade of NO synthase.
  • L-NAME infusion the blockade of NO synthase.
  • ADRA2b antagonist the effects on the coronary flow reserve (adenosine infusion as described above) after vehicle application and subsequently after administration of the ADRA2b antagonist are determined.
  • Vehicle and ADRA2b antagonist are administered intravenously as "bolus (50 ⁇ / kg) + infusion (infusion rate: 450 ⁇ / kg / h).
  • the influence of a substance on the size of the infarcted area (related to the underperfused risk area) in the rat can be determined and haemodynamic parameters of cardiac function can be recorded.
  • animals treated with substance were compared with animals receiving only placebo.
  • the method of acute myocardial infarction in the rat from a surgical procedure (under anesthesia and analgesia) in which a coronary artery, preferably the LAD (left anterior descending artery) ligated by a thread and reopened after a defined occlusion phase of 30min. After this time the vessel is reopened by loosening the suture (reperfusion of the heart tissue).
  • the thorax of the animal is closed again and the muscle layers and the epidermis with suture (Vicryl L 4-0 or 5-0 (V990H)) sewn.
  • the instrumentation of the animal is performed (introduction of a millarcatheter (2F) via the carotid artery for the measurement of cardiac hemodynamics).
  • the animals are killed painlessly after the measurements without re-awakening by an overdose of narcotics (isoflurane> 5%, pentobarbital> 200mg / kg) and / or blood withdrawal in deep anesthesia.
  • TTC staining Triphenyltetrazolium chloride (TTC), (vital staining) B4 Hemodynamic studies
  • Rats (strain WiWu) are pretreated with reserpine (5 mg / kg sc) for 3 days. This leads to an increased effect of adrenergic agonists and antagonists in the animals.
  • the blood pressure is measured invasively under anesthesia.
  • the animals are first given an iV dose of an antagonist, followed by iv administration of the ADRA2 agonist dexmedetomidine 3 ⁇ g / kg / min (15 min).
  • Selective ADRA2b antagonists counteract dose-dependent agonist-induced increases in blood pressure.
  • animals e.g., rats, dogs
  • the substances are preferably formulated in 0.9% sodium chloride solution, plasma / dimethlysulfoxide (99/1), polyethylene glycol / ethanol / water in the ratio 50/10/40 (other suitable formulating agents are possible).
  • Blood samples may be taken from the animals via catheter or venipuncture and collected in anticoagulant-containing (e.g., lithium-heparinate or potassium-EDTA) tubes.
  • anticoagulant-containing e.g., lithium-heparinate or potassium-EDTA
  • the test animals are sampled at the following times: 0.033, 0.083, 0.167, 0.25, 0.283, 0.333, 0.5, 0.75, 1, 2, 3, 5, 7, 24 hours after administration of the substance. (The decrease of lesser, further or later times is also possible.)
  • the blood samples are centrifuged to obtain plasma.
  • the supernatant (plasma) is removed and either further processed directly or frozen for later sample preparation.
  • sample preparation For sample preparation, mix 50 ⁇ plasma with 250 ⁇ acetonitrile (the precipitating reagent acetonitrile also contains the internal standard ISTD for subsequent analytical determination) and then allow to stand at room temperature for 5 minutes. Thereafter, the mixture is centrifuged for 3 minutes at 16000 g. The supernatant is removed and mixed with 500 ⁇ a matched to the mobile phase buffer. Samples are then analyzed by LC-MS / MS analysis (eg, liquid chromatography using a Gemini 5 ⁇ C18 110A 50x3mm (or 150x3mm) column from Phenomenex, mass spectrometry with an API 5500 or API 6500, SCIEX, Canada) to determine the concentration of the substance in the examined individual samples.
  • LC-MS / MS analysis eg, liquid chromatography using a Gemini 5 ⁇ C18 110A 50x3mm (or 150x3mm) column from Phenomenex, mass spectrometry with an API 5500 or API 6500, SCIEX
  • the concentration ratio of whole blood to plasma can also be determined for a particular substance.
  • the substance is incubated with a specific concentration for 20 minutes in whole blood. Subsequently, the preparation of the samples as described above to determine the concentration of the substance in the plasma. The set concentration divided by the measured concentration in the plasma gives the parameter Cb / Cp.
  • NCA non-compartmental analysis
  • CL pharmacokinetic parameters clearance
  • Vss volume of distribution
  • the compounds according to the invention can be converted into pharmaceutical preparations as follows: i.v. solution:
  • the compound of the invention is dissolved at a concentration below saturation solubility in a physiologically acceptable solvent (e.g., isotonic sodium chloride solution, glucose solution 5% and / or PEG 400 solution 30%).
  • a physiologically acceptable solvent e.g., isotonic sodium chloride solution, glucose solution 5% and / or PEG 400 solution 30%.
  • the solution is sterile filtered and filled into sterile and pyrogen-free injection 'containers.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne de nouvelles imidazopyridinamides substituées de la formule (I), leurs procédés de production, leur utilisation seules ou en combinaison pour le traitement et/ou la prévention de maladies ainsi que leur utilisation pour la production de médicaments destinés au traitement et/ou à la prévention de maladies, notamment au traitement et/ou à la prévention de maladies cardiovasculaires, neurologiques, du système nerveux central et métaboliques,
EP18785687.7A 2017-10-24 2018-10-18 Imidazopyridinamides substituées et leur utilisation Withdrawn EP3700903A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17198021 2017-10-24
PCT/EP2018/078653 WO2019081353A1 (fr) 2017-10-24 2018-10-18 Imidazopyridinamides substituées et leur utilisation

Publications (1)

Publication Number Publication Date
EP3700903A1 true EP3700903A1 (fr) 2020-09-02

Family

ID=60162133

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18785687.7A Withdrawn EP3700903A1 (fr) 2017-10-24 2018-10-18 Imidazopyridinamides substituées et leur utilisation

Country Status (27)

Country Link
US (1) US20200339567A1 (fr)
EP (1) EP3700903A1 (fr)
JP (1) JP2021500366A (fr)
KR (1) KR20200076686A (fr)
CN (1) CN111225917A (fr)
AR (1) AR113790A1 (fr)
AU (1) AU2018354785A1 (fr)
BR (1) BR112020007967A2 (fr)
CA (1) CA3084422A1 (fr)
CL (1) CL2020001075A1 (fr)
CO (1) CO2020004968A2 (fr)
CR (1) CR20200173A (fr)
CU (1) CU20200041A7 (fr)
DO (1) DOP2020000072A (fr)
EA (1) EA202091020A1 (fr)
EC (1) ECSP20023043A (fr)
IL (1) IL273954A (fr)
JO (1) JOP20200073A1 (fr)
MA (1) MA50440A (fr)
MX (1) MX2020004190A (fr)
NI (1) NI202000029A (fr)
PE (1) PE20201280A1 (fr)
PH (1) PH12020550472A1 (fr)
SG (1) SG11202003641RA (fr)
TW (1) TW201932462A (fr)
UY (1) UY37947A (fr)
WO (1) WO2019081353A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112384515A (zh) 2018-02-27 2021-02-19 因赛特公司 作为a2a/a2b抑制剂的咪唑并嘧啶和三唑并嘧啶
JP7391046B2 (ja) 2018-05-18 2023-12-04 インサイト・コーポレイション Ａ２ａ／ａ２ｂ阻害剤としての縮合ピリミジン誘導体
EP3818063A1 (fr) 2018-07-05 2021-05-12 Incyte Corporation Dérivés de pyrazine fusionnés en tant qu'inhibiteurs d'a2a/a2b
MX2021007426A (es) 2018-12-20 2021-09-08 Incyte Corp Compuestos de imidazopiridazina e imidazopiridina como inhibidores de cinasa-2 de tipo receptor de activina.
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
WO2020216669A1 (fr) * 2019-04-23 2020-10-29 Bayer Aktiengesellschaft Imidazopyridinamides substitués par un phényle et leur utilisation
WO2023086390A1 (fr) * 2021-11-09 2023-05-19 Tufts Medical Center, Inc. Procédés et compositions pour fournir une protection myocardique et traiter le stress myocardique et la fibrose
CN117510444B (zh) * 2024-01-06 2024-03-08 成都瑞尔医药科技有限公司 一种呋塞米的精制工艺

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
AU2001252609A1 (en) 2000-04-27 2001-11-12 Imperial Cancer Research Technology Ltd. Imidazopyridine derivatives
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
NZ530366A (en) 2001-07-20 2005-02-25 Juvantia Pharma Ltd Oy Compounds useful for treatment or prevention of disease mediated by alpha-2B-adrenoceptor
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
WO2008027812A2 (fr) 2006-08-28 2008-03-06 Forest Laboratories Holdings Limited Dérivés d'imidazopyridine et d'imidazopyrimidine
WO2008134553A1 (fr) 2007-04-26 2008-11-06 Xenon Pharmaceuticals Inc. Procédés de traitement de maladies associées aux canaux sodiques au moyen de composés bicycliques
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
GB0720041D0 (en) * 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
CA2737604C (fr) 2008-09-17 2017-08-29 Allergan, Inc. 3-amino-1-oxo ou thioxo-1,2,5,6,7,8-hexahydro-2,7-naphtyridine-4-carbonitriles substitues en tant qu'antagonistes selectifs d'alpha-2b
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
PE20130683A1 (es) 2010-02-27 2013-06-20 Bayer Ip Gmbh Ariltriazolonas ligadas a bisarilo y su uso
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
EP2671582B1 (fr) * 2011-02-01 2016-07-13 Kyowa Hakko Kirin Co., Ltd. Dérivé hétérocylique à cycles fusionnés
US8791162B2 (en) 2011-02-14 2014-07-29 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
DE102011007272A1 (de) 2011-04-13 2012-10-18 Bayer Pharma Aktiengesellschaft Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung
CN104619709B (zh) 2012-07-13 2016-11-09 Ucb生物制药私人有限公司 作为tnf活性调节剂的咪唑并吡啶衍生物
EP2875003B1 (fr) 2012-07-20 2016-11-16 Bayer Pharma Aktiengesellschaft Nouveaux acides carboxyliques de 5-aminotetrahydroquinoline-2-yl et leur utilisation
US9624214B2 (en) 2012-11-05 2017-04-18 Bayer Pharma Aktiengesellschaft Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
KR20150121007A (ko) * 2013-03-01 2015-10-28 바이엘 파마 악티엔게젤샤프트 트리플루오르메틸-치환된 고리-융합된 피리미딘 및 그의 용도
UY36383A (es) 2014-11-03 2016-06-01 Bayer Pharma AG Derivados de feniltriazol sustituido con hidroxialquilo y sus usos

Also Published As

Publication number Publication date
AR113790A1 (es) 2020-06-10
DOP2020000072A (es) 2020-08-31
MX2020004190A (es) 2020-08-03
JP2021500366A (ja) 2021-01-07
CL2020001075A1 (es) 2021-01-22
WO2019081353A1 (fr) 2019-05-02
JOP20200073A1 (ar) 2020-04-29
CA3084422A1 (fr) 2019-05-02
BR112020007967A2 (pt) 2020-10-20
CU20200041A7 (es) 2021-03-11
EA202091020A1 (ru) 2020-07-24
MA50440A (fr) 2020-09-02
TW201932462A (zh) 2019-08-16
PE20201280A1 (es) 2020-11-24
UY37947A (es) 2019-05-31
CR20200173A (es) 2020-06-26
IL273954A (en) 2020-05-31
CN111225917A (zh) 2020-06-02
ECSP20023043A (es) 2020-06-30
AU2018354785A1 (en) 2020-04-23
PH12020550472A1 (en) 2021-03-15
KR20200076686A (ko) 2020-06-29
CO2020004968A2 (es) 2020-05-05
SG11202003641RA (en) 2020-05-28
NI202000029A (es) 2020-10-09
US20200339567A1 (en) 2020-10-29

Similar Documents

Publication Publication Date Title
EP3700903A1 (fr) Imidazopyridinamides substituées et leur utilisation
EP3386979B1 (fr) Dérivés 2-phényl-3-(pipérazinométhyl)imidazo[1,2-a]pyridine en tant que bloquers de canaux task-1 et task-2 pour le traitement de troubles respiratoires du sommeil
EP3638675B1 (fr) Imidazopyrimidines à substitution diazabicyclique et leur utilisation pour traiter des maladies des voies respiratoires
EP3045456B1 (fr) Uracile substitue bicyclique et son utilisation
WO2015036560A1 (fr) Trifluorométhylpyrimidones substitués par un radical hétérocyclique et leurs utilisation
US10435403B2 (en) Positive allosteric modulators of muscarinic M2 receptor
EP3487856A1 (fr) Composés diazahétérobicycliques substitués et leur utilisation
WO2016037954A1 (fr) N,2-diarylquinoline-4-carboxamides substitués et utilisation desdits n,2-diarylquinoline-4-carboxamides substitués comme anti-inflammatoires
JP7295019B2 (ja) ７－置換１－アリール－ナフチリジン－３－カルボン酸アミドおよびその使用
EP3481823B1 (fr) Amides de l'acide 1-pyridyl-naphthyridin-3-carboxylique substitués en position 7, et leur utilisation
EP3707141B1 (fr) 2,4-dihydro-3h-1,2,4-triazol-3-ones substituées et leur utilisation
WO2016146602A1 (fr) N-bicyclo-2-arylchinolino-4-carboxamides substitués et leur utilisation
EP2556831A1 (fr) 6-Carbonitriles de 3,4-Dihydro-4-oxo-5-aryl-pyrido[2,3-d]pyrimidine en tant que ligand pour le récepteur Adenosin pour le traitement des maladies cardiovasculaires
WO2020216669A1 (fr) Imidazopyridinamides substitués par un phényle et leur utilisation
WO2018189011A1 (fr) N-aryléthyl-2-arylquinoléine-4-carboxamides substitués et leur utilisation
EP3296298A1 (fr) 1-aryl-naphtyridin-3-ylcarboxamides substitués en position 7 et leur utilisation
EP3455224B1 (fr) 5,6,7,8-tétrahydro[1,2,4]triazolo[4,3- a]pyridin-3(2h)-ones et 2,5,6,7-tétrahydro-3h-pyrrolo[2,1 -c][1,2,4]triazol-3-ones substituées et leur utilisation
WO2017153235A1 (fr) N-cyclo-3-aryl-1-naphthamides substitués et leur utilisation
WO2017153234A1 (fr) N-cyclo-2-arylchinolin-4-carboxamides substitués et leur utilisation

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200525

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RAV Requested validation state of the european patent: fee paid

Extension state: MA

Effective date: 20200525

Extension state: TN

Effective date: 20200525

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20210601

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20211012